로딩 중…
StockDiggingStockDigging

MEDIPOST Co., Ltd.

078160· KOSDAQ
₩9,520-6.21%
2026-06-19

Price Chart

MEDIPOST Co., Ltd.-19.39%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap373.23B KRW
Revenue73.90B KRW
Net Income-79.73B KRW
Total Assets577.70B KRW
Net Assets241.25B KRW
Employees648
Value
P/B1.55x
P/S5.05x
FCF Yield-16.09%
Profitability
ROE-33.05%
ROA-13.80%
Op. Margin-96.31%
Revenue Growth1.24%
Financial Health
Debt Ratio239.46%
Total Debt162.97B KRW
FCF-60.06B KRW
Cash102.54B KRW
Current Ratio1.08x
Performance
1Y Return-19.39%
1M Return-31.95%
From 52W High-67.29%
1Y MDD-66.46%
Trading
Volume147,595 shares
Foreign Own.3.59%
Per Share
EPS-2,061 KRW
BPS6,153 KRW

Company Info

CEO 오원일
Employees 648
Founded 2000
HQ 경기도 성남시, KR

Medipost, established in 2000 and listed on KOSDAQ in 2005, specializes in umbilical cord blood banking and stem cell therapy development. The company operates an umbilical cord blood bank, sells the degenerative arthritis treatment Cartistem, and develops umbilical cord blood-derived stem cell therapies. It also engages in the health functional food business, offering multivitamins and probiotics. Medipost is headquartered in Seongnam-si, Gyeonggi-do, and actively expands its market reach through awareness campaigns, global clinical trials for Cartistem, and diversified online marketing channels.